Distinct Effects of Familial Parkinson's Disease-Associated Mutations on α-Synuclein Phase Separation and Amyloid Aggregation

Biomolecules. 2023 Apr 23;13(5):726. doi: 10.3390/biom13050726.

Abstract

The Lewy bodies and Lewy neurites are key pathological hallmarks of Parkinson's disease (PD). Single-point mutations associated with familial PD cause α-synuclein (α-Syn) aggregation, leading to the formation of Lewy bodies and Lewy neurites. Recent studies suggest α-Syn nucleates through liquid-liquid phase separation (LLPS) to form amyloid aggregates in a condensate pathway. How PD-associated mutations affect α-Syn LLPS and its correlation with amyloid aggregation remains incompletely understood. Here, we examined the effects of five mutations identified in PD, A30P, E46K, H50Q, A53T, and A53E, on the phase separation of α-Syn. All other α-Syn mutants behave LLPS similarly to wild-type (WT) α-Syn, except that the E46K mutation substantially promotes the formation of α-Syn condensates. The mutant α-Syn droplets fuse to WT α-Syn droplets and recruit α-Syn monomers into their droplets. Our studies showed that α-Syn A30P, E46K, H50Q, and A53T mutations accelerated the formation of amyloid aggregates in the condensates. In contrast, the α-Syn A53E mutant retarded the aggregation during the liquid-to-solid phase transition. Finally, we observed that WT and mutant α-Syn formed condensates in the cells, whereas the E46K mutation apparently promoted the formation of condensates. These findings reveal that familial PD-associated mutations have divergent effects on α-Syn LLPS and amyloid aggregation in the phase-separated condensates, providing new insights into the pathogenesis of PD-associated α-Syn mutations.

Keywords: Parkinson’s disease (PD); amyloid aggregation; liquid–liquid phase separation (LLPS); mutation; phase transition; α-synuclein.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amyloid / genetics
  • Amyloid / metabolism
  • Amyloidogenic Proteins / metabolism
  • Humans
  • Lewy Bodies / metabolism
  • Mutation
  • Parkinson Disease* / metabolism
  • Point Mutation
  • alpha-Synuclein / genetics
  • alpha-Synuclein / metabolism

Substances

  • alpha-Synuclein
  • Amyloid
  • Amyloidogenic Proteins

Grants and funding

This work was supported by the National Natural Science Foundation of China grants (Nos. 32100546 and 31871425), the Natural Science Foundation of Jiangsu Province (BK20200036), Jiangsu Province’s Innovation Program (JSSCTD202142), the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD), the Six Talent Peaks Project in Jiangsu Province, the Postgraduate Research & Practice Innovation Program of Jiangsu Province.